Cite
MLA Citation
Robert Motzer et al.. “Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.” Lancet oncology, vol. 23, no. 6, 2022, pp. 768–780. http://access.bl.uk/ark:/81055/vdc_100155168665.0x00001f